

**From:** [REDACTED]  
**To:** [REDACTED]  
**Subject:** FW: Data from LSG in relation to inactivating materials and alternatives to VTM  
**Date:** 29 April 2020 07:28:51  
**Attachments:** [LSP-DOC-2468-\(ID 9761\) AQIX Medium Technical Information.pdf](#)  
[3\\_CellShip\\_Development\\_CGTC.PDF](#)

---

Hi [REDACTED]

Please find below the response from our Technical team in relation to the attached

Kind regards

## NHS Supply Chain Covid-19 Support

[REDACTED] Commercial | LDOC  
Defence Fuels Acquisition Programme (DFAP)  
MOD Abbey Wood, #3360 | Cedar 3a | Bristol | BS34 8JH  
Email: [REDACTED]



[Defence Equipment & Support](#)

---

**From:** [REDACTED]  
**Sent:** 28 April 2020 19:35  
**To:** [REDACTED]  
**Subject:** RE: Data from LSG in relation to inactivating materials and alternatives to VTM

Hi [REDACTED]

Sorry for the slow response on this. This medium is designed for maintaining cells in a viable state, which is not what we need for COVID-19 testing viral transport medium

Best wishes

[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED] | [www.deloitte.co.uk](http://www.deloitte.co.uk)

---

**From:** [REDACTED]  
**Sent:** 20 April 2020 11:55  
**To:** [REDACTED]  
**Subject:** [EXT] FW: Data from LSG in relation to inactivating materials and alternatives to VTM

Hi Both

Please see the below follow up from LSG in relation to the attached

Thanks

## NHS Supply Chain Covid-19 Support

[REDACTED] Commercial | LDOC  
Defence Fuels Acquisition Programme (DFAP)  
MOD Abbey Wood, #3360 | Cedar 3a | Bristol | BS34 8JH  
Email: [REDACTED]



Defence Equipment & Support

---

**From:** [REDACTED]  
**Sent:** 20 April 2020 11:33  
**To:** [REDACTED]  
[REDACTED]  
**Subject:** RE: Data from LSG in relation to inactivating materials and alternatives to VTM

Dear [REDACTED],

Aqix: This was developed to transport tissues and maintain cells in good function – it is a synthetic interstitial fluid and would do a very good job, much better than the saline. We have further developed this into CellStore – a product aimed at the transport of cells at ambient temperatures for cell and gene therapy techniques. I have attached some literature. This would be an idea product for transporting ‘live’ cells for testing, much better than the CDC protocol which is a basic cell culture medium. Salty water with bovine serum and antibiotics. Both Aqix and CellStore have sufficient data to allow it to be fast tracked to CE mark through the current system for Covid 19 as this would be for a very specific application, transport of cell samples for up to 96 hours.

I would love to send some samples to [REDACTED] for him to validate. I have copied [REDACTED] since this is her project and maybe [REDACTED] would like to discuss with [REDACTED].

Sorry to add to your task list.

Thanks

[REDACTED]

---

**From:** [REDACTED]  
**Sent:** 17 April 2020 15:56  
**To:** [REDACTED]  
**Subject:** FW: Data from LSG in relation to inactivating materials and alternatives to VTM

## NHS Supply Chain Covid-19 Support

[REDACTED] Commercial | LDOC  
Defence Fuels Acquisition Programme (DFAP)  
MOD Abbey Wood, #3360 | Cedar 3a | Bristol | BS34 8JH  
Email: [REDACTED]



Defence Equipment & Support

---

**From:** [REDACTED]

**Sent:** 15 April 2020 20:57

**To:** [REDACTED]

**Subject:** RE: Data from LSG in relation to inactivating materials and alternatives to VTM

Hi [REDACTED]

Thanks very much

Regarding the Aqix medium – it looks like it is designed specifically to keep mammalian cells alive in transit, which is very tricky, and not something we actually need (we just need the virus RNA to survive, which is much less hard). Given how specialist it is I suspect this will be much more expensive than standard VTM, and so unless they could supply it in very large quantities in CE-marked tubes of the right size I'm not sure it would be a priority right now

Best wishes

[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED] | [www.deloitte.co.uk](http://www.deloitte.co.uk)

---

**From:** [REDACTED]

**Sent:** 15 April 2020 15:59

**To:** [REDACTED]

**Subject:** [EXT] Data from LSG in relation to inactivating materials and alternatives to VTM

Hi Both

I am not sure who best to send these details to so I am starting here.

I have received the attached from LSG in relation to their Inactivating material guidance and also details on an option they believe may be suitable instead of VTM for WS2

If you can let me know your thoughts or who may be best to send these to.

Thanks

## NHS Supply Chain Covid-19 Support

Commercial | LDOC  
Defence Fuels Acquisition Programme (DFAP)  
MOD Abbey Wood, #3360 | Cedar 3a | Bristol | BS34 8JH  
Email: [REDACTED]



### Defence Equipment & Support

#### IMPORTANT NOTICE

This communication is from Deloitte LLP, a limited liability partnership registered in England and Wales with registered number OC303675. Its registered office is 1 New Street Square, London EC4A 3HQ, United Kingdom. Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see [www.deloitte.co.uk/about](http://www.deloitte.co.uk/about) to learn more about our global network of member firms. For details of our professional regulation please see [Regulators](#).

This communication contains information which is confidential and may also be privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s), please notify [xx.xxxxxxxx.xx@xxxxxxx.xx.xy](mailto:xx.xxxxxxxx.xx@xxxxxxx.xx.xy) and destroy this message immediately. Email communications cannot be guaranteed to be secure or free from error or viruses. All emails sent to or from a @deloitte.co.uk email account are securely archived and stored by an external supplier within the European Union.

You can understand more about how we collect and use (process) your personal information in our [Privacy Notice](#).

Deloitte LLP does not accept any liability for use of or reliance on the contents of this email by any person save by the intended recipient(s) to the extent agreed in a Deloitte LLP engagement contract.

Opinions, conclusions and other information in this email which have not been delivered by way of the business of Deloitte LLP are neither given nor endorsed by it.

#### IMPORTANT NOTICE

This communication is from Deloitte LLP, a limited liability partnership registered in England and Wales with registered number OC303675. Its registered office is 1 New Street Square, London EC4A 3HQ, United Kingdom. Deloitte LLP is the United Kingdom affiliate of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see [www.deloitte.co.uk/about](http://www.deloitte.co.uk/about) to learn more about our global network of member firms. For details of our professional regulation please see [Regulators](#).

This communication contains information which is confidential and may also be privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s), please notify [xx.xxxxxxxx.xx@xxxxxxx.xx.xy](mailto:xx.xxxxxxxx.xx@xxxxxxx.xx.xy) and destroy this message immediately. Email communications cannot be guaranteed to be secure or free from error or viruses. All emails sent to or from a @deloitte.co.uk email account are securely archived and stored by an external supplier within the European Union.

You can understand more about how we collect and use (process) your personal information in our [Privacy Notice](#).

Deloitte LLP does not accept any liability for use of or reliance on the contents of this email by any person save by the intended recipient(s) to the extent agreed in a Deloitte LLP engagement contract.

Opinions, conclusions and other information in this email which have not been delivered by way of the business of Deloitte LLP are neither given nor endorsed by it.